Reach Us +441414719275
Biobanking Of Stem Cells | 9629
ISSN: 2157-7552

Journal of Tissue Science & Engineering
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Biobanking of stem cells

2nd International Conference on Tissue Science & Regenerative Medicine

Julie G. Allickson

Symposium: J Tissue Sci Eng

DOI: 10.4172/2157-7552.S1.010

D iscussion will be focused on recent advances in the emerging and evolving field of biobanking including procurement, processing, preservation, and banking. Overview will include several different cell types that are stored for clinical use and cells stored for potential therapeutic applications including cell processing methodology. It will also explore regulatory considerations applicable to biobanking and describe the differences between private and public banking and associated regulations
Julie G. Allickson is the Director of Translational Research at Wake Forest Institute for Regenerative Medicine. Prior to joining the institute, she was an Executive Officer of the company and Vice President of Laboratory Operations and R & D at Cryo-Cell International, Inc., an AABB accredited, and Florida- based Family Cord Blood Bank. As Director of Translational Research she is responsible for the cGTP/cGMP-Compliant Facility, Quality Assurance, Quality Control and Regulatory Affairs associated with translation of the technology. As Vice President of the Laboratory she was responsible for all technical aspects of Laboratory Operations along with Research and Development activities associated with adult stem cells, including the development work related to isolation of a unique stem cell harvested from menstrual blood. Prior to this position, she worked for the University Of Miami School Of Medicine, Diabetes Research Institute as the Laboratory Director of the cGMP Hematopoietic Cell Processing Facility. She was responsible for the design and implementation of the State Licensed Clinical Flow Cytometry Laboratory. She was the lead in Regulatory Affairs for the processing laboratory of Islet and Hematopoietic Cell products which included oversight of all Investigational New Drugs (IND) and external regulations. Prior to working for the University of Miami she worked for the American Red Cross managing the Hematopoietic Cell Processing and Platelet Serology Laboratory. During her tenure at the American Red Cross she served as a member of the National Stem Cell Task Force and participated in the preparation of national protocols developed for Hematopoietic Cell Processing Laboratories. She was part of the team to perform the very first Bone Marrow Transplant at the University of Miami in 1990. She has 23 years of experience in Cellular Therapy, Cellular Processing and Regenerative Medicine. She has a Doctorate in Health Sciences along with a Master?s Degree in Medical Laboratory Sciences. She is one of the founding members of the International Society of Cellular Therapy in 1992 and has been a member of the American Association of Blood Banks (AABB) for 20 years. She has presented at national and international meeting related to adult stem cells. She is an inspector for Net Cord FACT and for AABB and is Chair of the AABB Standards Committee for Cell Therapy Product Services. She is also on the Technical Advisory Board for Tissue Engineered Products under ICCBBA